Welcome to our dedicated page for HEARTFLOW SEC filings (Ticker: HTFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heartflow, Inc. filings document a Nasdaq-listed Delaware medical technology company focused on AI software for coronary artery disease. Its recent 8-K reports furnish operating results, investor presentations and Regulation FD disclosures, while also recording capital-structure events tied to its completed initial public offering and repayment and termination of a credit agreement.
The company’s proxy materials cover annual meeting matters, director elections, auditor ratification and stockholder voting mechanics. As an emerging growth company, Heartflow’s filings also identify governance, exchange listing, financial reporting and public-company status disclosure areas relevant to a commercial-stage medical technology issuer.
Heartflow, Inc. Chief Financial Officer Vikram Verghese reported routine share dispositions related to tax withholding on vesting restricted stock units. On May 6, the issuer retained 1,536 shares of common stock at $30.29 per share, and on May 7 retained 473 shares at $29.98 per share. These 2,009 shares were withheld by the company to satisfy income tax obligations, not sold in the open market, and Verghese held 210,854 shares directly following the most recent transaction.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported routine tax-withholding share dispositions tied to restricted stock unit vesting. On May 6, 5,300 shares of common stock were withheld at $30.29 per share, and on May 7, 1,904 shares were withheld at $29.98 per share.
According to the footnote, these shares were retained by Heartflow to satisfy income tax withholding and remittance obligations in connection with previously reported RSU vesting and net settlement, rather than sold in the open market. Following these transactions, Farquhar directly holds 541,959 shares of Heartflow common stock.
Heartflow, Inc. disclosed that investment entities affiliated with Bain Capital Life Sciences, including BCLS Fund III Investments, LP, reported open-market sales of a combined 2,000,000 shares of Common Stock. The sales occurred on April 28–30, 2026 at weighted average prices generally between $29.00 and $31.46 per share.
The securities are held directly by BCLS Fund III Investments, LP, while related Bain Capital Life Sciences entities may be deemed to share voting and dispositive power and each disclaims beneficial ownership except to the extent of its pecuniary interest. After these transactions, the filing shows indirect holdings of up to 10,194,048 shares on the earliest reported date and 8,448,158 shares following the latest reported sale.
Heartflow, Inc. is asking stockholders to elect two Class I directors and ratify PricewaterhouseCoopers LLP as auditor at its 2026 annual meeting. The virtual-only meeting will be held on June 16, 2026 at 8:00 a.m. Pacific Time, with April 24, 2026 as the record date.
Seven directors serve on a classified board, and most are independent under Nasdaq rules. The proxy details 2025 director and executive pay, including stock option and RSU grants, a new clawback policy, anti-hedging rules, and a senior leadership severance policy tied to terminations and change in control.
Heartflow, Inc. Chief Executive Officer John C.M. Farquhar reported an open-market sale of 22,562 shares of Common Stock at $26.72 per share on April 10, 2026. After this trade, he directly holds 549,163 shares, indicating he retained the vast majority of his position.
The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, suggesting the transaction was scheduled in advance as part of a systematic trading program rather than a spur-of-the-moment decision.
HTFL affiliate filed a Form 144 to report proposed resale of 22,562 shares of Common Stock tied to a stock option exercise dated 06/25/2024. The filing also lists three dispositions by John C.M. Farquhar: 22,562 shares on 02/10/2026, 12,837 shares on 03/10/2026, and 9,725 shares on 03/18/2026, with proceeds shown for each transaction.
Heartflow, Inc. Chief Medical Officer Campbell Rogers exercised stock options and sold shares of common stock. On April 1, 2026, he exercised options covering 67,017 shares of common stock at exercise prices of $2.22 and $8.33 per share and received the same number of common shares.
That day, he sold 64,533 shares of common stock at a weighted average price of $24.64 per share in open-market transactions, as part of a Rule 10b5-1 Trading Plan adopted on September 12, 2025. Following these transactions, he holds 81,002 shares directly, along with indirect holdings through several trusts, including 50,754 shares held by The Campbell Rogers Revocable Trust.
HTFL notice of proposed sale under Rule 144 describing planned and recent disposals of Common Stock by named holders and options-related issuances.
The filing lists planned sales tied to prior stock option exercises (12/27/2019: 13,047 shares; 02/17/2021: 3,867 shares; 07/31/2025: 4 shares; 07/10/2023 grant exercised 47,615 shares) and shows actual sales in the past three months by related holders on 02/12/2026 and 03/19/2026 (examples: 16,918 and 47,615 shares with dollar proceeds reported).
Heartflow, Inc. ownership disclosure: HealthCor Partners Management, L.P. reports beneficial ownership of 2,082,014 shares of common stock, representing 2.4% of the class. The filing breaks this down as HealthCor Partners Fund, L.P. 1,248,939 shares (1.5%) and HealthCor Partners Fund II, L.P. 833,075 shares (1.0%). The filing notes a distribution by HCPCIV 1, LLC of 4,615,542 shares on March 24, 2026.